513 related articles for article (PubMed ID: 26694595)
1. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
3. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
4. Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid.
Lee KA; Kim J; Kim HJ; Kim HS
Int J Rheum Dis; 2021 Aug; 24(8):1053-1060. PubMed ID: 34184827
[TBL] [Abstract][Full Text] [Related]
5. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
Majumdar SR; Morin SN; Lix LM; Leslie WD
Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
[TBL] [Abstract][Full Text] [Related]
6. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
[TBL] [Abstract][Full Text] [Related]
7. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
Kaji H; Yamauchi M; Chihara K; Sugimoto T
Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
[TBL] [Abstract][Full Text] [Related]
8. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density.
Hayashi K; Yamamoto M; Murakawa Y; Yamauchi M; Kaji H; Yamaguchi T; Sugimoto T
Osteoporos Int; 2009 Nov; 20(11):1889-94. PubMed ID: 19387764
[TBL] [Abstract][Full Text] [Related]
9. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
Phan V; Blydt-Hansen T; Feber J; Alos N; Arora S; Atkinson S; Bell L; Clarson C; Couch R; Cummings EA; Filler G; Grant RM; Grimmer J; Hebert D; Lentle B; Ma J; Matzinger M; Midgley J; Pinsk M; Rodd C; Shenouda N; Stein R; Stephure D; Taback S; Williams K; Rauch F; Siminoski K; Ward LM;
Osteoporos Int; 2014 Feb; 25(2):627-37. PubMed ID: 23948876
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis management among chronic glucocorticoid users: a systematic review.
Albaum JM; Youn S; Levesque LE; Gershon AS; Cadarette SM
J Popul Ther Clin Pharmacol; 2014; 21(3):e486-504. PubMed ID: 25527817
[TBL] [Abstract][Full Text] [Related]
11. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.
Florez H; Hernández-Rodríguez J; Muxi A; Carrasco JL; Prieto-González S; Cid MC; Espinosa G; Gómez-Puerta JA; Monegal A; Guañabens N; Peris P
Rheumatology (Oxford); 2020 Jul; 59(7):1574-1580. PubMed ID: 31628810
[TBL] [Abstract][Full Text] [Related]
12. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders.
Ward LM; Ma J; Robinson ME; Scharke M; Ho J; Houghton K; Huber A; Scuccimarri R; Barsalou J; Roth J; Shenouda N; Matzinger MA; Lentle B; Jaremko JL; Koujok K; Watanabe Duffy K; Stein R; Sbrocchi AM; Rodd C; Miettunen PM; LeBlanc CMA; Larche M; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Sykes E; Konji VN; Rauch F; Siminoski K; Lang B
J Clin Endocrinol Metab; 2021 Nov; 106(12):e5195-e5207. PubMed ID: 34232311
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012.
Albaum JM; Lévesque LE; Gershon AS; Liu G; Cadarette SM
Osteoporos Int; 2015 Dec; 26(12):2845-52. PubMed ID: 26138581
[TBL] [Abstract][Full Text] [Related]
16. [Secondary osteoporosis. Glucocorticoid-induced osteoporosis: Threshold of bone mineral density for vertebral fracture].
Soen S
Clin Calcium; 2007 Mar; 17(3):399-402. PubMed ID: 17339745
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
[TBL] [Abstract][Full Text] [Related]
19. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]